LGND vs. IRWD, MNKD, INVA, DVAX, OPK, ARCT, NRIX, PRAX, GERN, and CMPS
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Arcturus Therapeutics (ARCT), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Geron (GERN), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.
In the previous week, Ironwood Pharmaceuticals and Ironwood Pharmaceuticals both had 3 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.76 beat Ironwood Pharmaceuticals' score of 0.59 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.
91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Ligand Pharmaceuticals has a net margin of 37.80% compared to Ligand Pharmaceuticals' net margin of -226.37%. Ironwood Pharmaceuticals' return on equity of 11.98% beat Ligand Pharmaceuticals' return on equity.
Ironwood Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Ironwood Pharmaceuticals currently has a consensus target price of $19.80, suggesting a potential upside of 153.20%. Ligand Pharmaceuticals has a consensus target price of $116.33, suggesting a potential upside of 64.85%. Given Ligand Pharmaceuticals' higher probable upside, equities analysts plainly believe Ironwood Pharmaceuticals is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals received 27 more outperform votes than Ironwood Pharmaceuticals when rated by MarketBeat users. Likewise, 69.92% of users gave Ligand Pharmaceuticals an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Ligand Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ligand Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
